Journal of Bone and Mineral Metabolism最新文献

{"title":"Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women.","authors":"Alyssa R Bailly, Garrett M Hester, Michaela G Alesi, Robert J Buresh, Yuri Feito, Christine M Mermier, Jeremy B Ducharme, Trisha A VanDusseldorp","doi":"10.1007/s00774-025-01592-0","DOIUrl":"10.1007/s00774-025-01592-0","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to investigate the effects of quercetin (a plant-based flavonoid) supplementation over 90 days on prominent bone turnover markers (BTMs), inflammatory markers, bone mineral density (BMD), body composition, and physical function in postmenopausal women.</p><p><strong>Materials and methods: </strong>Thirty-three healthy postmenopausal women were recruited to participate in a double-blind, placebo-controlled investigation. Participants were randomized into one of two supplement groups: (1) 500 mg of quercetin (QUE) once daily or (2) 500 mg of methylcellulose (placebo; PLB) once daily. Pre- and post-testing visits included assessments of BTMs (i.e., osteocalcin [OC], procollagen type I N-terminal propeptide [PINP], and type I collagen cross-linked C-terminal telopeptide [CTX]), inflammatory markers (i.e., interleukin [IL]-6, tumor necrosis factor-alpha [TNF-α], and C-reactive protein [CRP]), BMD measurements, body composition measurements, and physical function including timed up and go and handgrip strength.</p><p><strong>Results: </strong>The QUE group increased OC (p = 0.016; d = 0.89), PINP (p = 0.030; d = 0.64), and CTX (p = 0.023; d = 0.91) levels and decreased IL-6 (p = 0.045; d = 0.73) and TNF-α (p = 0.021; d = 0.90) levels compared to PLB. CRP (p = 0.448; d = 0.34), body composition (p > 0.05), and physical function (p > 0.05) remained unchanged.</p><p><strong>Conclusion: </strong>The results suggest that QUE may better assist in controlling a normal bone turnover cycle by mediating bone formation and decreasing pro-inflammatory cytokines. However, although within the accepted range, there was an increase in the bone resorption marker and therefore, it is unclear if QUE will protect against future bone loss. Nonetheless, additional research is necessary to evaluate the bone-conserving properties of QUE among postmenopausal women.</p><p><strong>Clinical trail registration: </strong>The ClinicalTrials.gov ID number: NCT05371340.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"304-314"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-contact electrical stimulation via a Vector-potential transformer promotes bone healing in drill-hole injury model.","authors":"Nao Yashima, Wataru Minamizono, Hiroya Matsunaga, Jiazheng Lyu, Kaoru Fujikawa, Hirai Suito, Takumi Okunuki, Shingo Nakai, Masafumi Ohsako","doi":"10.1007/s00774-025-01603-0","DOIUrl":"https://doi.org/10.1007/s00774-025-01603-0","url":null,"abstract":"<p><strong>Introduction: </strong>We investigated the effects of non-contact electrical stimulation via a Vector-potential (VP) transformer, a novel physical therapy device, on bone healing in drill-hole injury models.</p><p><strong>Materials and methods: </strong>Six-week-old male Wistar rats, after a one-week acclimation period, were divided into three groups: the control group (CO), the bone injury group (BI), in which a drill-hole injury was created, and the VP stimulation group (VP), which received non-contact electrical stimulation via a VP transformer after bone injury. In the VP group, rats underwent stimulation at 200 kHz for 30 minutes per day, seven days per week.</p><p><strong>Results: </strong>The VP group exhibited increased bone formation as early as day 7 post-injury, with significantly higher bone volume than the BI group at all time points (day 7: p = 0.0003; day 14: p = 0.0024; day 21: p = 0.0001). By day 21, the VP group showed lighter toluidine blue staining and reduced biglycan immunoreactivity compared to the BI group. Bone mineral density also increased (p = 0.0008). Osteoblasts in the VP group displayed abundant cytoplasm and a high capacity for osteocalcin synthesis. Additionally, the VP group demonstrated increased expression of Bglap (day 5: p = 0.0068; day 7: p = 0.0096) and Ctsk (day 7: p = 0.0329; day 14: p = 0.0171), along with a higher number of TRAP-positive osteoclasts (day 21: p = 0.0159) compared to the BI group.</p><p><strong>Conclusion: </strong>Non-contact electrical stimulation via a VP transformer promotes bone healing in drill-hole injury models.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limosilactobacillus reuteri with menaquinone-7 improves bone biomechanics and microarchitecture in ovariectomized mice: preliminary study.","authors":"Thaís Aguiar Santos, Jaqueline Lemes Ribeiro, Luisa Souza Battistelli, Ana Lia Anbinder","doi":"10.1007/s00774-025-01600-3","DOIUrl":"https://doi.org/10.1007/s00774-025-01600-3","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the effects of Limosilactobacillus reuteri (LR) and its combination with menaquinone-7 (MK-7; K) on ovariectomy-induced bone loss in mice and on bacterial growth in vitro.</p><p><strong>Methods: </strong>In the in vivo study, animals were divided into five groups: sham-operated (SHAM); ovariectomy (OVX); OVX-LR; OVX-K; OVX-LR-K. After 4 weeks of treatment, femur cortical biomechanical properties, vertebral microarchitecture, osteocalcin levels, Occludin and Jam3 expression, and intestinal histomorphometry were evaluated. In vitro, microbial growth was assessed by incubating L. reuteri with MK-7. After incubation, optical densities were measured, and bacteria were cultured on MRS agar for the colony-forming unit (CFU/ml) counting.</p><p><strong>Results: </strong>L. reuteri, MK-7, and their combination significantly improved femur intrinsic biomechanical properties and cortical vertebral thickness. The combined treatment exhibited a synergistic effect on the modulus of elasticity, and increased cortical vertebral volume and the villus/crypt ratio in comparison to OVX. L. reuteri and its combination with MK-7 restored vertebral trabecular microarchitecture values to SHAM levels. However, no significant differences were observed in serum levels of osteocalcin, Occludin or Jam3 expression among groups. In vitro, a significant increase in optical density and viable cell count was observed after 4 h of incubation.</p><p><strong>Conclusion: </strong>L. reuteri and its combination with MK-7 improved bone biomechanical and microarchitecture properties. We propose a synergistic preventive action of L. reuteri and MK-7 in estrogen-deficient mice. Additionally, the enhanced survival of L. reuteri in the presence of MK-7 may partially explain the observed benefits of the combined treatment in vivo.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing fracture incidence over 13 years in patients with rheumatoid arthritis from the IORRA cohort.","authors":"Takefumi Furuya, Eisuke Inoue, Hisashi Yamanaka, Masayoshi Harigai, Eiichi Tanaka","doi":"10.1007/s00774-025-01598-8","DOIUrl":"10.1007/s00774-025-01598-8","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate fracture incidence in patients with rheumatoid arthritis (RA) over 13 years in the Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort study.</p><p><strong>Materials and methods: </strong>The IORRA is a prospective observational cohort study of Japanese patients with RA. Between 2011 and 2023, 10,257 patients with RA were enrolled. Clinical parameters and data on fractures were collected biannually using self-reported questionnaires. The fracture incidence, standardized by sex, age, and Japanese Health Assessment Questionnaire score, was calculated for each two-year period.</p><p><strong>Results: </strong>From 2011 to 2023, the proportions of patients achieving Disease Activity Score in 28 joints remission, using biologic disease-modifying antirheumatic drugs, and taking osteoporosis medications increased (38.0% to 64.7%, 14.2% to 42.2%, and 31.6% to 38.3%, respectively), while the proportion of glucocorticoid use decreased (38.3% to 22.2%). The incidence of all and non-vertebral fractures increased from 47.2 and 36.7/1000 person-years in 2011 to 52.8 and 43.0/1000 person-years in 2023, respectively. Using 2023 as the reference, the standardized incidence ratios for all and non-vertebral fractures were: 2011-2012, 0.90 [95% confidence interval (CI) 0.82-0.98] and 0.86 (95% CI 0.78-0.95); 2013-2014, 0.88 (95% CI 0.81-0.96) and 0.84 (95% CI 0.76-0.93); 2015-2016, 0.94 (95% CI 0.86-1.02) and 0.89 (95% CI 0.80-0.98); 2017-2018, 0.97 (95% CI 0.88-1.07) and 0.94 (95% CI 0.84-1.05); 2019-2020, 0.95 (95% CI 0.84-1.07) and 0.93 (95% CI 0.81-1.06); 2021-2022, 1.00 (95% CI 0.89-1.13) and 0.99 (95% CI 0.86-1.13).</p><p><strong>Conclusion: </strong>Despite advancements in RA management over 13 years, fracture incidence may have increased in patients with RA.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplemental magnesium gluconate recovers osteoblastic Wntless ablation-induced degenerative bone complications.","authors":"Govinda Bhattarai, Ju-Hyeon An, Shankar Rijal, Junil Lee, Junhyeok Kim, Sung-Ho Kook, Jeong-Chae Lee, Eui-Sic Cho","doi":"10.1007/s00774-025-01599-7","DOIUrl":"https://doi.org/10.1007/s00774-025-01599-7","url":null,"abstract":"<p><strong>Introduction: </strong>Although numerous studies have highlighted the involvement of Wnt-mediated signaling in Mg ion-enhanced bone healing, whether Wnt-stimulated signaling is essential for the Mg ion-triggered bone repair and mass accrual is not yet completely understood.</p><p><strong>Materials and methods: </strong>We generated Wls^fl/fl wild-type (WT) control and their corresponding mutant (MT), Col2.3-Cre;Wls^fl/fl mice of osteoblastic Wntless (Wls) ablation and explored how supplemental magnesium gluconate (MgG) affects bone mass accrual and defected bone healing in relation to the Wls ablation.</p><p><strong>Results: </strong>Osteoblastic Wls ablation impaired bone mass accrual and bone healing along with age-related degenerative complications in bone marrow (BM) and BM cells. Oral supplementation of WT mice with MgG did not change natural bone mass accrual, but enhanced regenerative bone healing in femoral defects and the functionalities of BM cells. Supplemental MgG suppressed the Wls ablation-related bone loss and also stimulated new bone formation in the defects of MT mice. The MgG-induced beneficial effects in the MT mice were orchestrated with its potencies to ameliorate senescence, oxidative damage, and functional loss of BM and BM adherent cells, as well as to stimulate osteogenic activity.</p><p><strong>Conclusion: </strong>This study demonstrates that supplemental MgG is able to improve bone homeostatic maintenance by recovering age-related degenerative complications even at the lack of osteoblastic Wnt-stimulated signaling.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between vertebral fractures and comorbidities in patients with rheumatoid arthritis: a cross-sectional study.","authors":"Takeshi Mochizuki, Koichiro Yano, Naoko Otani, Ryo Hiroshima, Katsunori Ikari, Ken Okazaki","doi":"10.1007/s00774-025-01597-9","DOIUrl":"https://doi.org/10.1007/s00774-025-01597-9","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with rheumatoid arthritis (RA) are at an increased risk of osteoporosis and vertebral fractures. We investigated the risk factors for vertebral fractures and severe vertebral fractures in patients with RA, including comorbidities and urinary pentosidine levels.</p><p><strong>Materials and methods: </strong>This study included 637 patients with available clinical data on urinary pentosidine levels, vertebral fractures, and comorbidities. Vertebral fractures were evaluated using plain X-ray imaging. Comorbidities considered relevant to osteoporosis were type 2 diabetes mellitus, chronic kidney disease, and lung diseases.</p><p><strong>Results: </strong>The prevalence of vertebral fractures in this cohort was 30.1%. Patients with vertebral fracture Patients with vertebral fractures were significantly more likely to be older [odds ratio (OR) 1.075; 95% confidence interval (CI) 1.049-1.1.03], had higher prevalence of comorbidities (OR 1.770; 95% CI 1.138-2.753), higher urinary pentosidine levels (OR 1.028; 95% CI 1.013-1.044), higher history of non-vertebral fractures (OR 2.084; 95% CI 1.222-3.557), and lower total hip T-score (OR 0.526; 95% CI 0.329-0.841) than patients without vertebral fractures. Among patients with vertebral fractures, 54.2% had severe vertebral fractures. Patients with severe vertebral fractures were more likely to have lower lumbar spine T-scores (OR 0.768; 95% CI 0.622-0.949) than patients with non-severe vertebral fractures.</p><p><strong>Conclusions: </strong>This study identified factors associated with vertebral fractures and severe vertebral fractures in patients with RA. Notably, vertebral fractures were associated with comorbidities and urinary pentosidine levels. In patients with RA and vertebral fractures, low BMD in the lumbar spine was a significant factor associated with severe vertebral fractures.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of the weight-adjusted waist index with mortality in osteoporotic patients.","authors":"Qian Lyu, Linxiao Ma, Huijie Liu, Haiyan Shao","doi":"10.1007/s00774-025-01594-y","DOIUrl":"https://doi.org/10.1007/s00774-025-01594-y","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of osteoporosis (OP) is steadily rising, leading to a higher risk of mortality. This study assessed the impact of the Weight-Adjusted Waist Index (WWI) on osteoporosis-related mortality.</p><p><strong>Materials and methods: </strong>Data from NHANES 2005-2010, 2013-2014, and 2017-2018 were analyzed to evaluate the relationship between WWI and mortality in osteoporotic patients using weighted proportional hazards model and Kaplan-Meier survival analysis. A subgroup analysis was performed to ensure the stability of the findings.</p><p><strong>Results: </strong>The study included 1324 participants. The findings indicated a positive correlation between WWI and OP (OR 1.65, 95% CI 1.45-1.89). Among patients with OP, WWI showed a positive association with all-cause mortality (HR 1.28, 95% CI 1.10-1.48). There was no observed correlation between varying WWI levels and mortality due to cardiovascular disease or cancer.</p><p><strong>Conclusions: </strong>Maintaining a lower WWI is associated with a reduced risk of all-cause mortality among individuals with OP.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women.","authors":"Bingru Lu, Qunxiao Han, Shiyu Zhao, Shan Ding, Guolin Bao, Yiqing Liu","doi":"10.1007/s00774-025-01595-x","DOIUrl":"10.1007/s00774-025-01595-x","url":null,"abstract":"<p><strong>Introduction: </strong>To explore the associations between hormones, metabolic markers, and low bone mass in perimenopausal and postmenopausal women.</p><p><strong>Materials and methods: </strong>A total of 198 women were enrolled in this study. The correlations between hormones, metabolic markers, and BMD were analyzed. Risk factors for bone loss were identified. Receiver operating characteristic (ROC) curves were used to display the predictive power of these risk factors.</p><p><strong>Results: </strong>The years since menopause and the levels of glucose (GLU), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were inversely correlated with BMD, while estrogen and testosterone were positively correlated with BMD. Age (odds ratio [OR] 1.232; 95% confidence interval [CI] 1.106-1.372; p < 0.001), GLU (OR 1.848; 95% CI 1.116-3.059; p = 0.017), and FSH (OR 1.089; 95% CI 1.003-1.182; p = 0.042) were identified as risk factors for bone loss. Age (AUC = 0.884, 95% CI 0.833-0.935), FSH (AUC = 0.824, 95% CI 0.760-0.888), and GLU (AUC = 0.683, 95% CI 0.599-0.768) demonstrated significant discrimination capability for bone loss. The combined application of these factors resulted in a better prediction effect (AUC = 0.930, 95% CI 0.893-0.967).</p><p><strong>Conclusions: </strong>Age, FSH, and GLU were found to be specific risk factors for bone loss. The utilization of these factors offers compelling predictive power for bone loss in perimenopausal and postmenopausal women.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disulfiram ameliorates bone loss in ovariectomized mice by suppressing osteoclastogenesis.","authors":"Tatsuyuki Fukui, Asuka Terashima, Yasunori Omata, Ryota Chijimatsu, Kazuo Okamoto, Masayuki Tsukasaki, Yukiko Fukuda, Tadayoshi Hayata, Akiyoshi Saitoh, Etsuko Toda, Hiroshi Takayanagi, Sakae Tanaka, Yuya Terashima, Taku Saito","doi":"10.1007/s00774-024-01555-x","DOIUrl":"10.1007/s00774-024-01555-x","url":null,"abstract":"<p><strong>Introduction: </strong>Disulfiram (DSF), known as an anti-alcoholism drug, has been reported to suppress osteoclast differentiation in vitro; however, it remains uncertain whether DSF is effective in preventing osteoclastogenesis in vivo. This study aimed to investigate the effect of DSF administration in osteoporotic mice and its contribution to osteoclastogenesis in vivo.</p><p><strong>Materials and methods: </strong>The bone phenotype of ovariectomized mice, both treated and untreated with DSF, was examined using microcomputed tomography analysis. Osteoclastic and osteoblastic parameters were assessed through bone morphometric analysis. The direct effect of DSF on osteoblastogenesis in vitro was evaluated via a primary osteoblast culture experiment. The expression of genes related to DSF targets (Nup85, Ccr2, and Ccr5) in osteoclast-lineage cells was examined using scRNA-seq analysis and flow cytometry analysis using the bone marrow cells from ovariectomized mice. The impact of DSF on osteoclast-lineage cells was assessed using primary cultures of osteoclasts.</p><p><strong>Results: </strong>DSF administration ameliorated ovariectomy-induced bone loss and mitigated the increase of osteoclasts without affecting osteoblastogenesis. The scRNA-seq data revealed that osteoclast precursor cells expressed Nup85, Ccr2, and Ccr5. CCR2 and CCR5-positive cells in osteoclast precursor cells within bone marrow increased following ovariectomy, and this increase was canceled by DSF administration. Finally, we found that DSF had a significant inhibitory effect on osteoclastogenesis in the early stage by suppressing Tnfrsf11a expression.</p><p><strong>Conclusion: </strong>This study demonstrates that DSF could be a candidate for osteoporosis therapies because it suppresses osteoclastogenesis from an early stage in vivo.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"61-73"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of disease activity and gonadal status on bone mineral density and turnover in acromegaly.","authors":"Fabiana Freire Silva, Maria de Lourdes Lima, Clarissa Carvalho Pedreira, Marcos Almeida Matos","doi":"10.1007/s00774-024-01561-z","DOIUrl":"10.1007/s00774-024-01561-z","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to evaluate the impact of disease activity and gonadal status on bone mineral density (BMD) and turnover markers (BTMs) in individuals with acromegaly.</p><p><strong>Materials and methods: </strong>Subjects underwent laboratory tests for PTH, 25-hydroxyvitamin D, calcium, phosphorus, osteocalcin (OC) and C-telopeptide (CTX-1) and bone densitometry at the lumbar spine (LS), femoral neck (FN) and total hip (TH).</p><p><strong>Results: </strong>Sixty participants (48.6 ± 11.0 years; 66,7% female) were included in this cross-sectional study. Phosphorus, OC, CTX-1, and LS BMD were greater in the active disease group than in the controlled/cured disease group (P = 0.025, P < 0.001, P = 0.007, and P = 0.016, respectively). When analyzing gonadal status, phosphorus, OC and CTX-1 were greater in the hypogonadal group than in the eugonadal group (P = 0.017, P = 0.015, and P = 0.033, respectively). Patients with hypogonadism had a higher prevalence of reduced bone mass compared to eugonadal patients (44 vs. 17%, P = 0.023).</p><p><strong>Conclusion: </strong>This study revealed increased levels of phosphorus and BTMs in patients with active acromegaly. In this group, the greater LS BMD values are likely due to the anabolic effects of GH and IGF-1 and/or to the influence of LS arthropathy. Moreover, hypogonadism negatively impacts bone metabolism in acromegaly, leading to elevated BTMs and a higher prevalence of reduced bone mass in individuals affected by both conditions.</p>","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"123-132"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}